The incidence rate of herpes zoster in inflammatory bowel disease

A meta-analysis of cohort studies
Shih-Wei Lai, MDa,b, Kuan-Fu Liao, MD, PhDc,d, Cheng-Li Lin, MS,e,f, Yu-Hung Kuo, MSg, Chiu-Shong Liu, MD, MShi, Bing-Fang Hwang, PhDj,k

Abstract
Inflammatory bowel disease is associated with an increased risk of opportunistic infections. This study aimed to investigate the incidence rate of herpes zoster in patients with inflammatory bowel disease.

A meta-analysis was conducted by searching PubMed literature published from January 2000 to July 2019. The main outcome was the incidence rate of a new diagnosis of herpes zoster in patients previously diagnosed with inflammatory bowel disease. The incidence rate ratio (IRR) and 95% confidence interval (95% CI) for herpes zoster associated with inflammatory bowel disease was measured.

A total of 6 eligible cohort studies matching the entry criteria were included in the meta-analysis, providing 216,552 participants with inflammatory bowel disease and 790 events of herpes zoster among these participants with inflammatory bowel disease. The pooled incidence rate of developing herpes zoster was 10.41 per 1000 person-years in the inflammatory bowel disease group and 6.10 per 1000 person-years in the non-inflammatory bowel disease group, respectively. The meta-analysis demonstrated that patients with inflammatory bowel disease were associated with 1.68-fold increased risk of developing herpes zoster when compared to those without inflammatory bowel disease (IRR = 1.68, 95% CI = 1.53–1.84). Crohn disease and ulcerative colitis were associated with an increased risk of developing herpes zoster (IRR = 1.67, 95% CI = 1.40–1.98 for Crohn disease and IRR = 1.49, 95% CI = 1.34–1.65 for ulcerative colitis, respectively).

Patients with inflammatory bowel disease are at increased risk of developing herpes zoster. We suggest that the vaccination should be considered at the time of inflammatory bowel disease being diagnosed.

Abbreviations: 95% CI = 95% confidence interval, IRR = incidence rate ratio.

Keywords: herpes zoster, inflammatory bowel disease, meta-analysis, vaccination

1. Introduction
Herpes zoster develops when the latent varicella-zoster virus in human dorsal root ganglia is reactivated as the host’s immune functions decline.[1–3] The debilitating complication of herpes zoster is the pain caused by acute status of herpes zoster and postherpetic neuralgia.[1–3] Conditions which are associated with the impairment of the host’s immunity to varicella-zoster virus are recognized as the risk factors for herpes zoster, including autoimmune diseases, asthma, diabetes mellitus, chronic pancreatitis, corticosteroid therapy, age over 50, and others.[4–7] Inflammatory bowel disease is a chronic inflammation in the digestive system.
The association between inflammatory bowel disease and subsequent comorbidities has been investigated in previous meta-analysis, including depression, suicide, and others.\textsuperscript{[8–10]} An immunocompromised status related to inflammatory bowel disease itself or caused by immunosuppressive/immunomodulatory therapy has placed these patients more susceptible to bacterial, viral, or fungal infections.\textsuperscript{[11–15]} To date, existing epidemiological studies have shown that patients with inflammatory bowel disease are at higher risk of developing herpes zoster, but the incidence rates of herpes zoster in patients with inflammatory bowel disease varied from study to study, ranging from 7.54 per 1000 person-years to 18.34 per 1000 person-years.\textsuperscript{[16–22]} Given the great variety of the incidence rate of herpes zoster, if more evidence can be found, decision-making on vaccination against herpes zoster will be definite. The aim of this meta-analysis was to investigate the incidence rate of herpes zoster among the population of inflammatory bowel disease.

2. Methods

2.1. Search strategy

PubMed was used to search literature published from January 2000 to July 2019.

![Figure 1. Flow diagram of literature search.](image-url)

The following key words were applied to find out literature of interest: “inflammatory bowel disease”, “Crohn’s disease”, “ulcerative colitis”, “herpes zoster”, and “incidence”. The inclusion criteria were as followings: cohort studies including subjects with a baseline diagnosis of inflammatory bowel disease, Crohn disease, and/or ulcerative colitis; cohort studies using herpes zoster as a primary outcome. Figure 1 presents the flow diagram of literature search.

2.2. Data extraction

The qualification of each searched article was assessed by 3 authors according to the aforementioned key words and inclusion criteria (KFL, CLL, and YHK). Data on the following variables were extracted: the last name of the first author, the year of publication, the country where the study was conducted, the case number of inflammatory bowel disease, the case number of non-inflammatory bowel disease, the event number of herpes zoster, the follow-up person-years, and the incidence rate of herpes zoster. Disagreements were resolved through discussion and consensus with the 2 authors (CSL and BFH).

2.3. Major outcome

The major outcome was a new diagnosis of herpes zoster in patients previously diagnosed with inflammatory bowel disease.

2.4. Statistical analysis

The pooled estimate of the incidence rate ratio (IRR) and 95% confidence interval (CI) was calculated to investigate the association between inflammatory bowel disease and herpes zoster. Statistical heterogeneity was assessed based on the $I^2$ statistics, with $I^2 > 50\%$ meaning significant heterogeneity. A random-effects model was applied to combine an effect size if $I^2 > 50\%$. Statistical analyses were performed by using STATA statistical software version 14 (College Station, TX: StataCorp LP). Statistical significance was reached if a $P < .05$ was obtained.

2.5. Statement of ethics

The study was conducted in accordance with the Declaration of Helsinki. The ethical approval was waived because the study was a meta-analysis of retrospective data.

3. Results

3.1. Characteristics of eligible studies

Table 1 demonstrated the characteristics of the eligible studies. Totally, 6 eligible cohort studies were identified through our

| Author          | Country | Year | Event number of herpes zoster | Person-years | Incidence* |
|-----------------|---------|------|------------------------------|--------------|------------|
| Long et al, 2013| USA     | 2013 | 2677                         | 364,533      | 7.34       |
| Tsai et al, 2015| Taiwan  | 2015 | 381                          | 46,267       | 8.23       |
| Khan et al, 2018| USA     | 2018 | 321                          | 42,511       | 7.55       |
| Chang et al, 2018| Korea  | 2018 | 2340                         | 127,621      | 18.34      |
| Soh et al, 2019 | Korea   | 2019 | 2071                         | 142,729      | 14.51      |

| Author          | Country | Year | Event number of herpes zoster | Person-years | Incidence* |
|-----------------|---------|------|------------------------------|--------------|------------|
| Long et al, 2013| USA     | 2013 | 4340                         | 992,273      | 4.37       |
| Tsai et al, 2015| Taiwan  | 2015 | 1068                         | 185,902      | 5.74       |
| Khan et al, 2018| USA     | 2018 | 1076                         | 334,018      | 3.22       |
| Chang et al, 2018| Korea  | 2018 | 2,828,257                    | 250,552,299  | 11.29      |
| Soh et al, 2019 | Korea   | 2019 | 6672                         | 726,007      | 9.19       |

* Incidence: incidence rate, per 1000 person-years.
search strategy and were included in the meta-analysis. Gupta et al’s study did not demonstrate the overall incidence rate of herpes zoster among patients with inflammatory bowel disease,\textsuperscript{16} so it was not included in Table 1. There were 19753 patients with inflammatory bowel disease and 454 events of herpes zoster among 19753 patients with inflammatory bowel disease in Gupta et al’s study.\textsuperscript{16} The case number of inflammatory bowel disease ranged from 7055 to 108604. The event number of herpes zoster among patients with inflammatory bowel disease ranged from 321 to 2677. Totally, there were 216552 patients with inflammatory bowel disease and 7790 events of herpes zoster among 216552 patients with inflammatory bowel disease.

**Table 1.** Meta-analysis of incidence rate ratio of herpes zoster among patients with inflammatory bowel disease and non-inflammatory bowel disease controls

| Study                  | IRR (95% CI) | Weight |
|------------------------|--------------|--------|
| Long et al, 2013       | 1.68 (1.60, 1.76) | 21.30  |
| Tsai et al, 2015       | 1.43 (1.34, 1.53) | 20.17  |
| Khan et al, 2018       | 2.34 (2.07, 2.66) | 15.70  |
| Chang et al, 2018      | 1.62 (1.56, 1.69) | 21.69  |
| Soh et al, 2019        | 1.58 (1.50, 1.66) | 21.14  |
| Overall (I-squared = 92.0%, p = 0.000) | 1.68 (1.53, 1.84) | 100.00 |

**Figure 2.** (A) Forest plot demonstrating the incidence rate ratio of herpes zoster between patients with inflammatory bowel disease and non-inflammatory bowel disease controls (IRR = 1.68, 95% CI = 1.53–1.84). (B) Forest plot demonstrating the incidence rate ratio of herpes zoster between patients with Crohn disease and non-inflammatory bowel disease controls (IRR = 1.67, 95% CI = 1.40–1.98). (C) Forest plot demonstrating the incidence rate ratio of herpes zoster between patients with ulcerative colitis and non-inflammatory bowel disease controls (IRR = 1.49, 95% CI = 1.34–1.65). 95% CI = 95% confidence interval, IRR = incidence rate ratio.
zoster among patients with Crohn disease or ulcerative colitis, but it demonstrated the overall incidence rate of herpes zoster in patients with inflammatory bowel disease. Therefore, Gupta et al's and Khan et al's studies were included for a partial meta-analysis.

3.2. Overall risk of herpes zoster

All eligible studies were pooled to investigate the impact of prior diagnosis of inflammatory bowel disease on the risk of developing herpes zoster. We estimated that the pooled incidence rate of herpes zoster in the inflammatory bowel disease group was 10.41 per 1000 person-years. The pooled incidence rate of herpes zoster in the non-inflammatory bowel disease group was 6.10 per 1000 person-years.

Figure 2(A) demonstrated that inflammatory bowel disease was associated with an increased risk of developing herpes zoster when compared with non-inflammatory bowel disease (IRR = 1.68, 95% CI = 1.53–1.84). The sub-analysis demonstrated that Crohn disease was associated with an increased risk of developing herpes zoster (IRR = 1.67, 95% CI = 1.40–1.98, Fig. 2(B)). Ulcerative colitis was associated with an increased risk of developing herpes zoster (IRR = 1.49, 95% CI = 1.34–1.65, Fig. 2(C)).

3.3. Assessment of study quality

The Newcastle-Ottawa Scale system was used to assess the quality of the included studies. One of the 6 studies was scored as 7, and the scores of the other 5 studies were 8 (Table S1, Supplemental Digital Content, http://links.lww.com/MD2/A321). A Newcastle-Ottawa Scale score higher than 6 was considered as a high-quality study.

4. Discussion

In our meta-analysis, we observed that patients with inflammatory bowel disease were associated with a 1.68 times increased risk of developing herpes zoster. Similar risks were also detected in patients with Crohn disease and in patients with ulcerative colitis (IRR = 1.68 and IRR = 1.49, respectively). The underlying mechanism on the association between inflammatory bowel disease and herpes zoster was beyond the scope of our meta-analysis, we summarized the literature as follows. Inflammatory bowel disease itself can cause immune dysfunction and further places these patients at higher risk of developing bacterial, viral, or fungal infections. In addition, drug-induced immunosuppression related to the treatments of inflammatory bowel disease also places these patients at higher risk of developing bacterial, viral, or fungal infections.

All eligible studies included have shown the hazard ratio of developing herpes zoster. However, in the decision-making of public health and medical policy, it depends on the attributable risk rather than the hazard ratio. Without the data of incidence rate, the attributable risk cannot be estimated. In our meta-analysis, we estimated that the attributable risk of developing herpes zoster related to inflammatory bowel disease was 4.31 per 1000 person-years in our meta-analysis. As mentioned in previous articles, inflammatory bowel disease cannot be preventable or curable, but herpes zoster can be preventable by vaccination. Live vaccines are generally contraindicated in patients with immunosuppressive status. The CDC suggests that a live attenuated herpes zoster vaccine is contraindicated in patients on a substantially immunosuppressive steroid dose ≥2 weeks of daily receipt of 20mg or 2mg/kg body weight of prednisone or equivalent. However, clinical studies demonstrated that patients with inflammatory bowel disease on
immunosuppressive therapy or immuno-modulatory therapy did not have serious adverse events after receiving a live attenuated herpes zoster vaccine, and patients who received a live attenuated herpes zoster vaccine did not develop herpes zoster after vaccination during the study period.\[28,29\] According to the guidelines published by American College of Gastroenterology in 2017, all patient with inflammatory bowel disease aged 50 years and older should be suggested to receive 1 dose of live attenuated herpes zoster vaccine at least 1 month before starting immunosuppressive therapy.\[30\] Given that our meta-analysis supported patients with inflammatory bowel disease having a higher risk of developing herpes zoster, we suggest that the vaccination should be considered earlier than 50 years old and maybe at the time of inflammatory bowel disease being diagnosed.

To date, only 21% of patients with inflammatory bowel disease disease have received the herpes zoster vaccine because they were concerned of the efficacy and adverse events.\[28,31\] One cohort study demonstrated that the live attenuated herpes zoster vaccine could reduce the incidence of herpes zoster in patients with inflammatory bowel disease compared with those unvaccinated (4.09 vs 6.97 per 1000 patient-years).\[12\] In this cohort study, the number needed to vaccinate to prevent 1 case of herpes zoster is 347. In other word, only 1 case of inflammatory bowel disease would get the benefit from vaccination, but the other 346 cases did not get the benefit. Whether the cost-effectiveness of live attenuated herpes zoster vaccine is significant or not remains to be determined. A new adjuvanted recombinant herpes zoster vaccine has been proven to be cost-effective as compared with no vaccination, and to be cost-saving as compared with a live attenuated herpes zoster vaccine.\[33–35\] Observational studies have demonstrated that the number of patients who needed vaccination to prevent 1 event of herpes zoster was around 10 to 12 for the adjuvanted recombinant zoster vaccine and around 45 to 117 for the alive attenuated zoster vaccine.\[36,37\] In addition, the adjuvanted recombinant herpes zoster vaccine is not contraindicated in immunocompromised patients.\[33,38\] Further research is needed to determine the efficacy of the adjuvanted recombinant herpes zoster vaccine in patients with inflammatory bowel disease. The guidelines should be updated to suggest immunocompromised patients to receive recombinant instead of live vaccination.

5. Limitation

Some limitations need to be mentioned. First, theoretically we should compare patients with inflammatory bowel disease on pharmacotherapy and those patients not on pharmacotherapy. It was less likely to find patients with inflammatory bowel disease who did not take any medications. It was difficult to design a cohort study using such inclusion criteria. Some studies demonstrated that patients with inflammatory bowel disease who were exposed to thiopurines, anti-tumor necrosis factor-alpha, combination therapy, or corticosteroids were at increased risk for developing herpes zoster.\[17,19\] It was difficult to exclude the possibility that some treatment for inflammatory bowel disease would lead to an increased risk of developing herpes zoster in our meta-analysis. Second, not all relevant studies have shown the follow-up person-years. Without these data, it is difficult to measure the incidence rate of herpes zoster. We recommend that future studies investigating the incidence rate of herpes zoster should provide the event number and the follow-up person-years. Then researchers and scholars specializing in this field are able to test these published data. Third, age plays an important role in the risk of developing herpes zoster. Studies included did not provide the details of age distribution, so we were not able to measure the incidence rate of herpes zoster stratified by age. Similarly, our meta-analysis could not rule out the impacts of sex and other factors on the risk of developing herpes zoster. It indicates a future research direction that age, sex, and other factors should be included when conducting a meta-analysis of herpes zoster.

6. Conclusion

Patients with inflammatory bowel disease are at increased risk of developing herpes zoster. From a point of primary prevention, vaccination carries an indication to prevent future herpes zoster and postherpetic neuralgia. We suggest that the vaccination should be considered earlier than 50 years old and maybe at the time of inflammatory bowel disease being diagnosed. Great efforts should be made to elevate the vaccinated rate among these high risk patients.\[31\]

Author contributions
Shih-Wei Lai contributed to the conception of the article, initiated the draft of the article, and has approved the final draft submitted. Shih-Wei Lai and Kuan-Fu Liao contributed equally to the article. Kuan-Fu Liao, Cheng-Li Lin, and Yu-Hung Kuo conducted data analysis. Chiu-Shong Liu and Bing-Fang Hwang interpreted the data and contributed equally to the article.

Conceptualization: Shih-Wei Lai.

Formal analysis: Kuan-Fu Liao, Cheng-Li Lin, Yu-Hung Kuo, Chiu-Shong Liu, Bing-Fang Hwang.

Writing – original draft: Shih-Wei Lai.

References

[1] Bader MS. Herpes zoster: diagnostic, therapeutic, and preventive approaches. Postgrad Med 2013;125:78–91.
[2] Dayan RR, Peleg R. Herpes zoster - typical and atypical presentations. Postgrad Med 2017;129:567–71.
[3] Schmader K. Herpes zoster. Ann Intern Med 2018;169:FTC19–31.
[4] Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc 2017;92:1806–21.
[5] Lai SW, Lin CL, Liao KF. Chronic pancreatitis correlates with increased risk of herpes zoster in a population-based retrospective cohort study. J Hepatobiliary Pancreat Sci 2018;25:412–7.
[6] Lai SW, Lin CL, Liao KF. Case-control study examining the association between herpes zoster and oral corticosteroids use in older adults. Eur Geriatr Med 2018;9:707–12.
[7] Le P, Rothberg M. Herpes zoster infection. BMJ 2019;10k:5095.
[8] Alexakis C, Kumar S, Saxena S, Pollok R. Systematic review with meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease. Aliment Pharmacol Ther 2017;46:225–35.
[9] Zhang C, Byrne G, Lee T, Singer J, Giustini D, Bressler B. Incidence of suicide in inflammatory bowel disease: a systematic review and meta-analysis. J Can Assoc Gastroenterol 2018;1:107–14.
[10] Chen WT, Chi CC. Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol 2019;155:1022–7.
[11] Cote-Daigneault J, Peirani F, MacMahon E, Delaporte E, Rahier J-F, Colombel J-F. Management and prevention of herpes zoster in the immunocompromised inflammatory bowel disease patient: a clinical quandary. Inflamm Bowel Dis 2016;22:2538–47.
[12] Rodriguez de Santiago E, Albillos Martinez A, Lopez-Sanroman A. Infections in inflammatory bowel disease. Med Clin (Barc) 2017;148:415–23.
Borman ZA, Cote-Daigneault J, Colombel JF. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Rev Gastroenterol Hepatol 2018;12:1101–8.

Sagami S, Kobayashi T, Hibi T. Prevention of infectious diseases due to immunosuppression and vaccinations in Asian patients with inflammatory bowel disease. Inflamm Intest Dis 2018;3:1–10.

Farshidpour M, Charabaty A, Mattar MC. Improving immunization strategies in patients with inflammatory bowel disease. Ann Gastroenterol 2019;32:247–56.

Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1483–90.

Loog MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:420–9.

Tsai SY, Yang TY, Lin CL, Tsai Y-H, Kuo C-F, Kao C-H. Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. Int J Clin Pract 2015;69:228–34.

Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol 2018;16:1919–27. e3.

Chang K, Lee HS, Kim YJ, et al. Increased risk of herpes zoster infection in patients with inflammatory bowel diseases in Korea. Clin Gastroenterol Hepatol 2018;16:1928–36. e2.

Soh H, Chun J, Han K, et al. Increased risk of herpes zoster in young and metabolically healthy patients with inflammatory bowel disease: a nationwide population-based study. Gut Liver 2019;13:333–41.

Cote-Daigneault J, Bessisow T, Nicolae MV, et al. Herpes zoster incidence in inflammatory bowel disease patients: a population-based study. Inflamm Bowel Dis 2019;25:914–8.

Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Cited May 1, 2020.

Lai SW. Inflammatory bowel disease and the risk of herpes zoster. Gut Liver 2019;13:582.

Liao KF, Lai SW. Increased incidence of herpes zoster infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2019;25:e119.

Huber F, Ehrenesperger B, Hatz C, Chappuis F, Bühler S, Eperon G. Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics. J Travel Med 2018;25:1–8.

Centers for Disease Control and Prevention, USA. Vaccine Recommendations and Guidelines of the ACIP: Contraindications and Precautions. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html. Cited December 1, 2019.

Wasan SK, Zallouw S, Berg A, Chieifetz AS, Ganley-Leal L, Farraye FA. Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression. Inflamm Bowel Dis 2016;22:1391–6.

Khan N, Shah Y, Trivedi C, Lewis JD. Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. Aliment Pharmacol Ther 2017;46:668–72.

Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017;112:241–58.

Khan N, Trivedi C, Kavani H, Lewis J, Yang Y-X. Frequency of herpes zoster vaccination among inflammatory bowel disease patients. Inflamm Bowel Dis 2019;25:345–51.

Khan N, Trivedi C, Kavani H, Medvedeva E, Lewis J, Yang Y-X. Efficacy of live attenuated herpes zoster vaccine in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019;17:1341–7.

Syed YF. Recombinant zoster vaccine (Shingrix(R)): a review in herpes zoster. Drugs Aging 2018;35:1031–40.

Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccin Immunother 2019;15:772–7.

Curran D, Patterson B, Varghese L, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine 2018;36:3037–43.

van Oorschot DAM, Hunjan M, Bracke B, Lorenc S, Curran D, Starkie-Camejo H. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. BMJ Open 2019;9:e025553.

de Boer PT, van Lier A, de Melker H, et al. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med 2018;16:228.

Shah RA, Limmer AL, Nwannunu CE, Patel RR, Mui UN, Tyring SK. Shingrix for herpes zoster: a review. Skin Therapy Lett 2019;24:5–7.